These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 19123026)

  • 1. Profile of breast cancer in a group of women in a developing country in South Asia: is there a difference?
    Lokuhetty MD; Ranaweera GG; Wijeratne MD; Wickramasinghe KH; Sheriffdeen AH
    World J Surg; 2009 Mar; 33(3):455-9. PubMed ID: 19123026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis.
    Rosen PP; Lesser ML; Arroyo CD; Cranor M; Borgen P; Norton L
    J Clin Oncol; 1995 Apr; 13(4):821-30. PubMed ID: 7707107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Basal-like immunophenotype markers and prognosis in early breast cancer.
    Cassol L; Silveira Graudenz M; Zelmanowicz A; Cancela A; Werutsky G; Rovere RK; Garicochea B
    Tumori; 2010; 96(6):966-70. PubMed ID: 21388060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Demographic, tumour, and treatment characteristics of female patients with breast cancer in Sri Lanka; results from a hospital-based cancer registry.
    Wijeratne DT; Gunasekera S; Booth CM; Promod H; Jalink M; Jayarajah U; Seneviratne S
    BMC Cancer; 2021 Nov; 21(1):1175. PubMed ID: 34732162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of estrogen receptor, progesterone receptor and HER2 results in concurrent ipsilateral samples with invasive breast carcinoma: a retrospective study of 246 biopsies from 119 patients.
    Singh K; Wang Y; Marketkar S; Kalife ET; Steinhoff MM
    Hum Pathol; 2017 Jul; 65():123-132. PubMed ID: 28457730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Her2-Neu expression in ductal adenocarcinomas of the breast gland: correlation with histopathological parameters and estrogen receptors' expression in Mexican patients].
    Brück P; Vilches Cisneros N; Ramos López E; Barboza Quintana O; Ancer Rodríguez J; Flores Gutiérrez JP
    Ginecol Obstet Mex; 2006 Oct; 74(10):516-22. PubMed ID: 21961357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers.
    Nofech-Mozes S; Trudeau M; Kahn HK; Dent R; Rawlinson E; Sun P; Narod SA; Hanna WM
    Breast Cancer Res Treat; 2009 Nov; 118(1):131-7. PubMed ID: 19189211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya.
    Sayed S; Moloo Z; Wasike R; Bird P; Oigara R; Govender D; Kibera J; Carrara H; Saleh M
    Breast; 2014 Oct; 23(5):591-6. PubMed ID: 25012047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemistry subtypes (ER/PR/HER) of breast cancer: where do we stand in the West of Saudi Arabia?
    Khabaz MN
    Asian Pac J Cancer Prev; 2014; 15(19):8395-400. PubMed ID: 25339035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological value of somatostatin type 2A and estrogen receptor immunoreactivity in human breast carcinoma.
    Pilichowska M; Kimura N; Suzuki A; Yoshida R; Schindler M; Nagura H
    Endocr Pathol; 2001; 12(1):55-61. PubMed ID: 11478269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aggressive estrogen-receptor-positive breast cancer arising in patients with elevated body mass index.
    Santa-Maria CA; Yan J; Xie XJ; Euhus DM
    Int J Clin Oncol; 2015 Apr; 20(2):317-23. PubMed ID: 24913910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and prognostic role of triple-negative breast cancer by race: a surveillance study.
    Swede H; Gregorio DI; Tannenbaum SH; Brockmeyer JA; Ambrosone C; Wilson LL; Pensa MA; Gonsalves L; Stevens RG; Runowicz CD
    Clin Breast Cancer; 2011 Oct; 11(5):332-41. PubMed ID: 21729670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of cell cycle markers in well-differentiated lobular and ductal carcinomas.
    Soslow RA; Carlson DL; Horenstein MG; Osborne MP
    Breast Cancer Res Treat; 2000 May; 61(2):161-70. PubMed ID: 10942102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2 as a prognostic factor in breast cancer.
    Ménard S; Fortis S; Castiglioni F; Agresti R; Balsari A
    Oncology; 2001; 61 Suppl 2():67-72. PubMed ID: 11694790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population-based Study of Prosigna-PAM50 and Outcome Among Postmenopausal Women With Estrogen Receptor-positive and HER2-negative Operable Invasive Lobular or Ductal Breast Cancer.
    Lænkholm AV; Jensen MB; Eriksen JO; Roslind A; Buckingham W; Ferree S; Nielsen T; Ejlertsen B
    Clin Breast Cancer; 2020 Aug; 20(4):e423-e432. PubMed ID: 32253134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of age distribution patterns for different histopathologic types of breast carcinoma.
    Anderson WF; Pfeiffer RM; Dores GM; Sherman ME
    Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1899-905. PubMed ID: 17035397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The associations between mast cell infiltration, clinical features and molecular types of invasive breast cancer.
    Sang J; Yi D; Tang X; Zhang Y; Huang T
    Oncotarget; 2016 Dec; 7(49):81661-81669. PubMed ID: 27835573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients.
    Esteban JM; Felder B; Ahn C; Simpson JF; Battifora H; Shively JE
    Cancer; 1994 Sep; 74(5):1575-83. PubMed ID: 7914825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.
    Fernandes RC; Bevilacqua JL; Soares IC; Siqueira SA; Pires L; Hegg R; Carvalho FM
    Histopathology; 2009 Sep; 55(3):346-52. PubMed ID: 19723150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High incidence and frequency of LOH are associated with aggressive features of high-grade HER2 and triple-negative breast cancers.
    Tokunaga E; Okada S; Yamashita N; Akiyoshi S; Kitao H; Morita M; Kakeji Y; Maehara Y
    Breast Cancer; 2012 Apr; 19(2):161-9. PubMed ID: 21063923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.